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Hepatitis B virus (HBV) integration into the host genome has been implicated in the causation of hepatocel-
lular carcinoma (HCC). In this issue of Cancer Cell, Lau and colleagues report an HBV integration site recur-
rent in HCC that generates a chimeric transcript with oncogenic function as an RNA (but not protein) through
stimulation of Wnt/b-catenin signaling.Hepatocellular carcinoma (HCC) is one of
the few cancers directly caused by a virus
(both hepatitis B virus [HBV] and hepatitis
C virus) and is thus preventable by vacci-
nation. Worldwide, HCC is the fifth most
common cancer and the second most
common cause of cancer mortality, espe-
cially impacting developing countries
(Jemal et al., 2011). HBV is endemic to
sub-Saharan Africa and East Asia; thus,
the disparity of HCC epidemiology in
developed versus developing nations re-
flects the intimate relationship that HBV
plays in causing HCC. Globally, the lead-
ing cause of HCC is HBV. Other major
causative factors include hepatitis C virus
and alcohol consumption (El-Serag and
Rudolph, 2007).
HBV has been implicated in HCC devel-
opment via three mechanisms: direct
action from the viral protein X (HBx)
stimulating cell proliferation, chronic he-
patic inflammation caused by immune
response to the virus, and disruption of
chromosomes and genes by viral inser-
tion into the host genome. The ability of
HBV to integrate into the human genome
has been implicated in HCC oncogenesis
for many decades (Brechot et al., 1980),
but the mechanism through which
HBV integration gives rise to HCC is
not clearly understood. High-throughput
sequencing-based approaches now
enable large-scale detection of viral inte-
gration and are a promising avenue for un-
derstanding how HBV integration leads to
HCC. A recent transcriptome sequencing
(i.e., RNA-seq) study of HBV-positive
HCC samples discovered multiple recur-
rent insertion sites of the virus into various
protein-coding genes (Sung et al., 2012),and, in this issue of Cancer Cell, Lau
et al. (2014) discover a highly recurrent
insertion event in HCC wherein HBV inte-
grates into a transposable LINE1 element.
Transposable elements are DNA parti-
cles that can change their genomic loca-
tion. They are widespread in the human
genome, where they are known to still
be mobile. By nature of being able
to ‘‘jump around’’ the genome, poten-
tially landing within genes, transposable
elements are known mutagens. LINE1 el-
ements are known to be particularly mo-
bile, and their insertion into and disruption
of genes has been implicated in many dis-
eases, including cancer (Lee et al., 2012),
with a recent study describing a handful of
LINE1 insertions that contribute to HCC
(Shukla et al., 2013). These studies impli-
cate LINEs in carcinogenesis through
a mechanism of LINE element insertion
into genes, disrupting normal cellular
function. However, the study by Lau
et al. (2014) is intriguing for its discovery
not of a LINE element insertion into a
host gene, but of an HBV gene insertion
into a LINE element, which in turn pro-
duces an oncogenic HBV-LINE1 chimeric
transcript.
In their study, Lau et al. (2014) analyzed
RNA-seq data from six HCC cell lines,
searching for viral-human transcript fu-
sions. They found multiple instances of
chimeric transcripts resulting from HBV
integration, but, remarkably, one partic-
ular insertion event of the gene encoding
hepatitis B X protein (HBx) into a LINE1-
element on chromosome 8p11.21 (HBx-
LINE1) was recurrent among the HCC
tissue samples used for validation of the
fusion candidates. This chimeric tran-Cancer Cell 2script was found in 21 of the 90 HCC sam-
ples analyzed, while the next most preva-
lent fusion was only found in 2 samples. In
addition to its recurrence, Lau et al. (2014)
found that HBx-LINE1 is also a significant
prognosticator of survival in these HCC
patients. Through a series of RNAi exper-
iments in a cell line harboring the HBx-
LINE1 fusion, the authors show that
HBx-LINE1 confers migration, invasion,
and colony formation capabilities. Addi-
tionally, HBx-LINE1 was found to facili-
tate an epithelial-to-mesenchymal transi-
tion, supporting cell motility. The authors
further investigated this function of
HBx-LINE1, showing that the chimeric
transcript is capable of activating Wnt
signaling as manifested by its ability to
induce nuclear localization of b-catenin.
Addition of HBx-LINE1 to an immortal-
ized human hepatocyte cell line was able
to recapitulate many of the oncogenic
behaviors lost by RNAi knockdown. Inter-
estingly, only the full length chimeric HBx-
LINE1 transcript was able to reconstitute
oncogenesis; vectors containing just the
HBx portion or just the LINE1 portion
were unable to do so. The HBx-LINE1
transcript produces an 87 amino acid pro-
tein with 5 of the amino acids coded for by
LINE1, but the authors present compel-
ling evidence that this protein is not
actually participating in the oncogenic
activities observed. They generated a
mutant HBx-LINE1 vector with an early
stop codon and validated that this tran-
script did not produce the 87 amino
acid protein. However, this mutant HBx-
LINE1 was able to fully recapitulate all
observable oncogenic functions, sug-
gesting that HBx-LINE1 may serve a role5, March 17, 2014 ª2014 Elsevier Inc. 259
Figure 1. Coding andNoncodingOncogenicGene Fusions inCancer
(A) Schematic of classic fusion events giving rise to cancer via expression of a
chimeric protein. Well-known oncogenic fusions include BCR-ABL in chronic
myelogenous leukemia, EML4-ALK in lung cancer, and TMPRSS2-ERG in
prostate cancer.
(B) Lau et al. (2014) discovered that approximately 23% of HBV-positive hepa-
tocellular carcinomas harbor an integration of the hepatitis B X protein gene
(HBx) into a LINE1 element in chromosome 8. This integration leads to expres-
sion of the HBx-LINE1 fusion transcript, which mediates its oncogenic effects
independent of the protein it encodes.
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Previewssimilar to a long noncoding
RNA (lncRNA) as a functional
mRNA molecule. Finally, Lau
et al. (2014) generated a
transgenic mouse model ex-
pressing the chimeric tran-
script and showed that,
when exposed to a carcino-
genic agent, these mice ac-
quired more hepatic tumors
with stronger nuclear local-
ization of b-catenin than
control mice treated with
carcinogen.
lncRNAs are long, spliced,
polyadenylated RNA mole-
cules that do not have protein
coding potential. They have
been widely studied in the
past decade and have been
implicated in multiple pathol-
ogies, including cancer (Pre-
nsner and Chinnaiyan, 2011).
The HBx-LINE1 transcript
identified by Lau et al. (2014)seems to function similar to an lncRNA,
despite coding for a large protein. This
phenomenon is compelling, because it
highlights the possibility that many of the
thousands of coding genes may have
mRNAs that possess functions indepen-
dent of the protein they generate. One
other prominent example of mRNAs
serving a role independent of the pro-
teins they encode is competing endoge-
nous RNAs (ceRNAs). mRNAs serve as
ceRNAs by acting as miRNA ‘‘sponges,’’
which provide miRNA binding sites to
modulate free miRNA levels in the cell
(Salmena et al., 2011). The field of
mRNA functionality (outside of protein-
coding capacity) is still in its infancy.
Lau et al.’s study of the HBx-LINE1
transcript falls at an exciting intersection260 Cancer Cell 25, March 17, 2014 ª2014 Eof cancer biology with the fields of retro-
transposons, viral DNA mutagenesis,
and functional mRNA. Of the HCC sam-
ples analyzed by Lau et al. (2014),
23.3% bear the precise integration identi-
fied of HBx into LINE1, strongly sug-
gesting that formation of HBx-LINE1 is
selected for in HCC oncogenesis. Analo-
gous to recurrent protein-coding fusions
such as BCR-ABL in leukemia, EML4-
ALK in lung cancer, and TMPRSS2-ERG
in prostate cancer (Prensner and Chin-
naiyan, 2009) (Figure 1A), HBx-LINE1
likely represents the oncogenic driver mu-
tation in a subset of HCC. However, unlike
those examples, HBx-LINE1 is, to date,
unique, in that it does not mediate
oncogenic activity through the protein it
produces (Figure 1B). Further investiga-lsevier Inc.tion into the mechanism
by which the HBx-LINE1
chimeric transcript partici-
pates in the causation of
HCC will be beneficial to
understanding HCC biology,
developing therapies target-
ing HCC, and deciphering
oncogenic mechanisms of
long RNAs (whether they are
coding or noncoding).REFERENCES
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